MedTrace Logo

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-04-08

No results posted yet for this study

Summary

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

Conditions

  • Relapsed/Refractory B-cell Lymphomas
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Marginal Zone Lymphoma (MZL)
  • Mantle Cell Lymphoma (MCL)
  • Small Lymphocytic Lymphoma (SLL)
  • Primary Mediastinal Large B Cell Lymphoma
  • Transformed Follicular Lymphoma
  • Waldenstrom Macroglobulinemia
  • Lymphoplasmacytic Lymphoma
  • Burkitt Lymphoma

Interventions

COMBINATION_PRODUCT

CLBR001 and SWI019

No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy

Sponsors & Collaborators

  • Calibr, a division of Scripps Research

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2025-10-06
Completion
2025-10-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04488354 on ClinicalTrials.gov